Home › Research › Laboratory science
Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy
Maj‐Linda B. Selenica, Milene Lara Brownlow, Jeffy P. Jimenez, Daniel C. Lee, Gabriela Pena, Chad A. Dickey, Marcia N. Gordon, Dave Morgan. Neurodegenerative Diseases, 2012-07-10
Topic: Brain proteins, microglia and lab models
Plain-language summary
Acute injections of Aβ oligomers had no effect on p-tau epitopes but did result in elevation of phosphorylated/activated GSK3 (pGSK3). Chronic infusion of Aβ oligomers into the right hippocampus resulted in 3- to 4-fold elevations in several p-tau isoforms with no changes in total tau levels. A significant elevation in pGSK3 accompanied these changes. Microglial staining with CD68 paralleled the increase in tau phosphorylation, however, CD45 staining was unaffected by Aβ. Control experiments revealed that the infusion of Aβ from the minipumps was largely complete by 10 days after implantation. Thus, the elevation in p-tau 2 months after implantation implies that the changes are quite persistent. Soluble Aβ(1-42) oligomers have long-lasting effects on tau phosphorylation in the rTg4510 model, possibly due to elevations in GSK3. These data suggest that even brief elevations in Aβ production, may have enduring impact on the risk for tauopathy.
What this study adds
Evidence grade: Low
In a mouse model of tauopathy, chronic infusion of amyloid beta oligomers into the hippocampus caused 3- to 4-fold elevations in several p-tau isoforms with no changes in total tau levels, while acute injections had no effect on p-tau epitopes. The authors suggest that even brief elevations in amyloid beta production may have enduring impact on the risk for tauopathy, though this is animal research.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Selenica, M. B., Brownlow, M. L., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., et al. (2012). Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy. Neurodegenerative Diseases. https://doi.org/10.1159/000337230
Vancouver
Selenica MB, Brownlow ML, Jimenez JP, Lee DC, Pena G, Dickey CA, et al. Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy. Neurodegenerative Diseases. 2012. doi:10.1159/000337230. PMID: 22796753.
BibTeX
@article{selenica2012-22796753,
author = {Selenica, Maj‐Linda B. and Brownlow, Milene Lara and Jimenez, Jeffy P. and Lee, Daniel C. and Pena, Gabriela and Dickey, Chad A. and Gordon, Marcia N. and Morgan, Dave},
title = {{Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy}},
journal = {Neurodegenerative Diseases},
year = {2012},
doi = {10.1159/000337230},
pmid = {22796753},
url = {https://doi.org/10.1159/000337230}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Acute injections of Aβ oligomers had no effect on p-tau epitopes but did result in elevation of phosphorylated/activated GSK3 (pGSK3).
- Chronic infusion of Aβ oligomers into the right hippocampus resulted in 3- to 4-fold elevations in several p-tau isoforms with no changes in total tau levels.
- A significant elevation in pGSK3 accompanied these changes.
- Microglial staining with CD68 paralleled the increase in tau phosphorylation, however, CD45 staining was unaffected by Aβ.
- Control experiments revealed that the infusion of Aβ from the minipumps was largely complete by 10 days after implantation.
Why it matters
In a mouse model of tauopathy, chronic infusion of amyloid beta oligomers into the hippocampus caused 3- to 4-fold elevations in several p-tau isoforms with no changes in total tau levels, while acute injections had no effect on p-tau epitopes. The authors suggest that even brief elevations in amyloid beta production may have enduring impact on the risk for tauopathy, though this is animal research.
Study details
- Evidence strengthLow
How this study scored 40/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here and still being cited, so those were left out: it earned 29 of the 72 points we could judge it on, which is 40 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurodegenerative Diseases) |
| Journal's citation record | 1 / 4 | Neurodegenerative Diseases: journal h-index 80 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2012 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Laboratory or animal study (title names “mouse”) — scores zero |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | Citation count not trusted: 69 of 395 library studies citing it were published more than a year before it - a sign OpenAlex merged several works under this DOI — left out of this score |
| Citations per year | — / 5 | Citation count not trusted (see above) — left out of this score |
| Impact for its field and year | — / 6 | Citation count not trusted (see above) — left out of this score |
| Cited by studies here | — / 6 | Library citations not trusted (see above) — left out of this score |
| Still being cited | — / 4 | Citation count not trusted (see above) — left out of this score |
| Senior author's track record | 3 / 4 | Last-listed author Dave Morgan: h-index 52 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of South Florida: institution h-index 806 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 22796753) |
| Free to read | 2 / 2 | Free to read |
| Points | 29 / 72 | Scored on 15 of 20 parts. We have no data for the rest, so they are left out: 29 of the 72 points we could judge it on is 40 out of 100. |
| Total | 40 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.
Later studies that cite this one
395 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Laboratory science from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.